Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
28,862,345
-
Total 13F shares
-
20,144,110
-
Share change
-
-208,399
-
Total reported value
-
$225,005,701
-
Put/Call ratio
-
188%
-
Price per share
-
$11.17
-
Number of holders
-
129
-
Value change
-
-$8,699,698
-
Number of buys
-
67
-
Number of sells
-
68
Institutional Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) as of Q3 2023
As of 30 Sep 2023,
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) was held by
129 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,144,110 shares.
The largest 10 holders included
ARMISTICE CAPITAL, LLC, BlackRock Inc., FARALLON CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, BRAIDWELL LP, MILLENNIUM MANAGEMENT LLC, NORTHERN TRUST CORP, Krensavage Asset Management, LLC, Assenagon Asset Management S.A., and MORGAN STANLEY.
This page lists
129
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.